Artificial intelligence (AI) is rapidly evolving from an exclusive association with major tech companies to a vital component across various industries, particularly in healthcare and biotechnology. Eli Lilly (LLY), a global pharmaceutical leader specializing in diabetes, oncology, immunology, and neuroscience, exemplifies this trend as it leverages AI to enhance drug discovery, development, and delivery processes.
Currently valued at $901.8 billion, LLY stock has experienced a 12% decline year-to-date (YTD), contrasting with the S&P 500 Index’s drop of 4%. In the lengthy and complex process of bringing a drug to market, which can span over a decade, AI is poised to expedite the identification of viable drug candidates, optimize clinical trials, and reduce failure rates. As part of its innovation strategy, Lilly is heavily investing in AI technology, including a recent collaboration with Nvidia (NVDA) to establish a co-innovation AI lab aimed at merging cutting-edge computing with scientific expertise to accelerate drug discovery.
Thanks to its AI-driven initiatives, Lilly currently boasts 36 active Phase 3 programs and has initiated 14 new late-stage trials, marking one of the most substantial clinical pipelines in its history. Among its promising candidates are two obesity and metabolic drugs, Orforglipron and Retatrutide, which have shown favorable clinical results in late-stage trials. This ambitious pipeline is supported by Lilly’s significant capital investments; since 2020, the company has allocated over $55 billion toward expanding manufacturing capabilities. New facilities in the U.S. and Europe are set to enhance production capacity, allowing Lilly to manufacture 1.8 times more incretin doses in 2025 compared to the previous year. Additionally, Lilly announced plans to acquire Centessa Pharmaceuticals (CNTA) for approximately $6.3 billion, which will bring new OX2R agonists targeting sleep-wake disorders into its portfolio, including cleminorexton, a promising treatment for narcolepsy.
On April 1, LLY stock surged 3.7% following the U.S. Food and Drug Administration’s approval of Foundayo (orforglipron), Lilly’s once-daily oral obesity treatment. This medication aims to broaden access to obesity care, with costs starting at $25 per month for commercially insured patients and $149 for self-pay individuals. The convenience of Foundayo, which requires no meal or water limitations, is expected to boost its adoption, thereby solidifying Lilly’s position in the burgeoning obesity market. In 2025, Lilly reported an impressive revenue increase of 45% year-over-year (YoY), amounting to $65.2 billion, primarily driven by strong global demand and volume growth across major markets, including the U.S., Europe, Japan, and China. The company maintained a high gross margin of 83.2%, while adjusted net earnings surged by 96% to $22.95 per share.
Looking ahead, Lilly anticipates revenue for 2026 to range between $80 billion and $83 billion, indicating approximately 25% growth at the midpoint, with earnings per share (EPS) projected to increase by 49% at the midpoint to between $33.50 and $35 per share. In the healthcare arena, AI is not just expediting drug discovery; it is also improving patient outcomes and creating entirely new markets. Eli Lilly is showcasing that when AI is harmonized with experience, capital, and execution, it can generate substantial competitive advantages. Analysts forecast Lilly’s earnings to rise by 43.2% in 2026, followed by a 21.3% increase in 2027.
On Wall Street, Eli Lilly has achieved an overall “Strong Buy” rating. Out of the 30 analysts covering the stock, 23 have designated it a “Strong Buy,” three a “Moderate Buy,” and four recommend a “Hold.” The average analyst price target of $1,238.46 suggests a 30% potential increase from current levels, with the highest estimate reaching $1,500, indicating the stock could rally by as much as 57% over the coming year.
On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are solely for informational purposes. This article was originally published on Barchart.com.
See also
Finance Ministry Alerts Public to Fake AI Video Featuring Adviser Salehuddin Ahmed
Bajaj Finance Launches 200K AI-Generated Ads with Bollywood Celebrities’ Digital Rights
Traders Seek Credit Protection as Oracle’s Bond Derivatives Costs Double Since September
BiyaPay Reveals Strategic Upgrade to Enhance Digital Finance Platform for Global Users
MVGX Tech Launches AI-Powered Green Supply Chain Finance System at SFF 2025
